Literature DB >> 29698389

Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples.

Rui Xue Zhang1,2, Jason Li1, Tian Zhang1, Mohammad A Amini1, Chunsheng He1, Brian Lu1, Taksim Ahmed1, HoYin Lip1, Andrew M Rauth, Xiao Yu Wu1.   

Abstract

Nanotechnology has been applied extensively in drug delivery to improve the therapeutic outcomes of various diseases. Tremendous efforts have been focused on the development of novel nanoparticles and delineation of the physicochemical properties of nanoparticles in relation to their biological fate and functions. However, in the design and evaluation of these nanotechnology-based drug delivery systems, the pharmacology of delivered drugs and the (patho-)physiology of the host have received less attention. In this review, we discuss important pharmacological mechanisms, physiological characteristics, and pathological factors that have been integrated into the design of nanotechnology-enabled drug delivery systems and therapies. Firsthand examples are presented to illustrate the principles and advantages of such integrative design strategies for cancer treatment by exploiting 1) intracellular synergistic interactions of drug-drug and drug-nanomaterial combinations to overcome multidrug-resistant cancer, 2) the blood flow direction of the circulatory system to maximize drug delivery to the tumor neovasculature and cells overexpressing integrin receptors for lung metastases, 3) endogenous lipoproteins to decorate nanocarriers and transport them across the blood-brain barrier for brain metastases, and 4) distinct pathological factors in the tumor microenvironment to develop pH- and oxidative stress-responsive hybrid manganese dioxide nanoparticles for enhanced radiotherapy. Regarding the application in diabetes management, a nanotechnology-enabled closed-loop insulin delivery system was devised to provide dynamic insulin release at a physiologically relevant time scale and glucose levels. These examples, together with other research results, suggest that utilization of the interplay of pharmacology, (patho-)physiology and nanotechnology is a facile approach to develop innovative drug delivery systems and therapies with high efficiency and translational potential.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29698389      PMCID: PMC5943915          DOI: 10.1038/aps.2018.33

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  170 in total

1.  Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.

Authors:  Ho Lun Wong; Reina Bendayan; Andrew Mike Rauth; Xiao Yu Wu
Journal:  J Control Release       Date:  2006-09-26       Impact factor: 9.776

2.  In vivo performance and biocompatibility of a subcutaneous implant for real-time glucose-responsive insulin delivery.

Authors:  Michael K L Chu; Claudia R Gordijo; Jason Li; Azhar Z Abbasi; Adria Giacca; Oliver Plettenburg; Xiao Yu Wu
Journal:  Diabetes Technol Ther       Date:  2015-02-11       Impact factor: 6.118

Review 3.  Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.

Authors:  Jennifer I Hare; Twan Lammers; Marianne B Ashford; Sanyogitta Puri; Gert Storm; Simon T Barry
Journal:  Adv Drug Deliv Rev       Date:  2016-04-29       Impact factor: 15.470

4.  Intratumoral hypoxia, radiation resistance, and HIF-1.

Authors:  Gregg L Semenza
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

5.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

Review 6.  Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles.

Authors:  Ho Lun Wong; Reina Bendayan; Andrew M Rauth; Yongqiang Li; Xiao Yu Wu
Journal:  Adv Drug Deliv Rev       Date:  2007-05-01       Impact factor: 15.470

Review 7.  Carbonic anhydrase IX: regulation and role in cancer.

Authors:  Martin Benej; Silvia Pastorekova; Jaromir Pastorek
Journal:  Subcell Biochem       Date:  2014

Review 8.  Targeting metastasis.

Authors:  Patricia S Steeg
Journal:  Nat Rev Cancer       Date:  2016-04       Impact factor: 60.716

Review 9.  Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells.

Authors:  Christine Dufès; Majed Al Robaian; Sukrut Somani
Journal:  Ther Deliv       Date:  2013-05

Review 10.  Single agent versus combination chemotherapy for metastatic breast cancer.

Authors:  Sue Carrick; Sharon Parker; Charlene E Thornton; Davina Ghersi; John Simes; Nicholas Wilcken
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15
View more
  13 in total

1.  A new platform for international collaboration on pharmacology and drug development: 2017 China-Canada-USA Pharmacology/Physiology Conference.

Authors:  Zhong-Ping Feng; Hong-Shuo Sun
Journal:  Acta Pharmacol Sin       Date:  2018-05       Impact factor: 6.150

2.  Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplatin Combination for Improved Therapeutic Outcome in Pancreatic Cancer.

Authors:  Mubin Tarannum; Md Akram Hossain; Bryce Holmes; Shan Yan; Pinku Mukherjee; Juan L Vivero-Escoto
Journal:  Small       Date:  2021-11-10       Impact factor: 13.281

3.  Combination targeting of 'platelets + fibrin' enhances clot anchorage efficiency of nanoparticles for vascular drug delivery.

Authors:  Michael Sun; Kenji Miyazawa; Tejal Pendekanti; Amaya Razmi; Emre Firlar; Stephanie Yang; Tolou Shokuhfar; Oliver Li; Wei Li; Anirban Sen Gupta
Journal:  Nanoscale       Date:  2020-10-16       Impact factor: 7.790

Review 4.  Advances of nanomaterials-based strategies for fighting against COVID-19.

Authors:  Chunxi Zeng; Xucheng Hou; Margaret Bohmer; Yizhou Dong
Journal:  View (Beijing)       Date:  2021-05-05

5.  Dose Effects of Orally Administered Spirulina Suspension on Colonic Microbiota in Healthy Mice.

Authors:  Jinlu Hu; Yaguang Li; Sepideh Pakpour; Sufang Wang; Zhenhong Pan; Junhong Liu; Qingxia Wei; Junjun She; Huaixing Cang; Rui Xue Zhang
Journal:  Front Cell Infect Microbiol       Date:  2019-07-05       Impact factor: 5.293

Review 6.  Emerging Nano- and Micro-Technologies Used in the Treatment of Type-1 Diabetes.

Authors:  Rosita Primavera; Bhavesh D Kevadiya; Ganesh Swaminathan; Rudilyn Joyce Wilson; Angelo De Pascale; Paolo Decuzzi; Avnesh S Thakor
Journal:  Nanomaterials (Basel)       Date:  2020-04-20       Impact factor: 5.076

7.  A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.

Authors:  Aïda Falgàs; Victor Pallarès; Ugutz Unzueta; María Virtudes Céspedes; Irene Arroyo-Solera; María José Moreno; Jorge Sierra; Alberto Gallardo; María Antonia Mangues; Esther Vázquez; Antonio Villaverde; Ramon Mangues; Isolda Casanova
Journal:  Haematologica       Date:  2019-06-27       Impact factor: 9.941

8.  A Study of Vanadate Group Substitution into Nanosized Hydroxyapatite Doped with Eu3+ Ions as a Potential Tissue Replacement Material.

Authors:  Nicole Nowak; Rafal Jakub Wiglusz
Journal:  Nanomaterials (Basel)       Date:  2021-12-28       Impact factor: 5.076

9.  Nanoantioxidant-Based Silica Particles as Flavonoid Carrier for Drug Delivery Applications.

Authors:  Francisco Arriagada; Germán Günther; Javier Morales
Journal:  Pharmaceutics       Date:  2020-03-26       Impact factor: 6.321

10.  Selective delivery of T22-PE24-H6 to CXCR4+ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model.

Authors:  Aïda Falgàs; Victor Pallarès; Naroa Serna; Laura Sánchez-García; Jorge Sierra; Alberto Gallardo; Lorena Alba-Castellón; Patricia Álamo; Ugutz Unzueta; Antonio Villaverde; Esther Vázquez; Ramon Mangues; Isolda Casanova
Journal:  Theranostics       Date:  2020-04-06       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.